Gedea Biotech secures 1.3 MEuros (14 MSEK) to advance its antibiotic-free vaginal infection treatment pHyph towards market launch
Lund, Sweden, May 24, 2023: Gedea Biotech today announced that it has raised 1.3 MEuros (14 MSEK) for additional development activities of their product pHyph for antibiotic free treatment of vaginal infections. The funds will be used for:
- An ongoing proof-of-concept study for the treatment of Vulvo Vaginal Candidiasis (VVC) with pHyph, partially financed by a recent grant from Swelife and Medtech4Health
- Investigating how the vaginal microbiome changes during short- and long-term treatment with pHyph in patients with bacterial vaginosis
- Preparation of an additional clinical study for the treatment of bacterial vaginosis, planned to start after the summer.
Current as well as new shareholders from Family Offices and Business Angels with a track record as life science investors participated in the funding round.
Vaginal infections affect at least 400 million women worldwide every year, but with current treatments, the risk of recurrence is substantial as antimicrobial resistance also rapidly increases. pHyph has shown a clinical cure rate for bacterial vaginosis on par with antibiotics on the market, with a superior safety profile and without causing secondary VVC infections as is the case with antibiotics.
"We are delighted to have succeeded in raising more funds for our additional clinical documentation of pHyph and also to investigate its wider impact on the vaginal microbiome. We particularly welcome the engagement by the new shareholders," says Annette Säfholm, CEO of Gedea Biotech. "The commitment from new, experienced life science investors to support our journey validates the trust in our company and our plans for the further development of pHyph”.
Chairman of the board Ton Berkien adds: “In the current, rather harsh climate for investments, it is quite an achievement to raise funds within life sciences, and I would like to express my thanks to both current and new investors and welcome them warmly to be part of the exciting Gedea journey”.
For more information please contact:
Annette Säfholm, CEO Gedea Biotech
Telephone: +46 708 - 91 86 81
Email: annette.safholm@gedeabiotech.com
Ton Berkien, Chairman, Gedea Biotech
Telephone: +46 70- 791 49 54
Email: ton.berkien@gedeabiotech.com
About pHyph
The vaginal tablet, pHyph will treat bacterial vaginosis (BV) and prevent recurrence by promoting a healthy vaginal microbiome, restoring the vaginal pH to its normal level of pH 4,0 - 4,5 and by breaking down the biofilm formed during BV under which the infectious bacteria begin to thrive. These mechanisms of actions, together provide a beneficial environment for the healthy vaginal microbiome. The naturally occurring active ingredient GDA 001 in pHyph is well documented and is already approved as a food additive. A clinical cure rate for BV on par with antibiotics on the market, has been proven in two phase 2 trials, with a superior safety profile and without causing secondary VVC infections as antibiotics do.
About Gedea Biotech
Gedea Biotech is a Swedish, innovative women’s health company developing pHyph, the first antibiotic free treatment that will both treat and prevent bacterial vaginosis. Vaginal infections affect at least 400 million women every year worldwide and the market is worth over $ 1.5 billion. Gedea Biotech was founded in 2015 in Lund, Sweden. https://gedeabiotech.com/
About Medtech4Health
Medtech4Health strive to increase the number and quality of new innovative products and services within medtech. In collaboration with patients, healthcare, academia, and business, we contribute to increasing value for people affected by disease in their everyday lives. Medtech4Health is funded by the Swedish government through the Swedish innovation authority Vinnova, Swedish Energy Agency and Swedish Research Council for Sustainable Development Formas, and by the programme’s partners.
www.medtech4health.se
#innovation #medtech #medicinteknik #hälsa #health @medtech4health @swelife @vinnova
About Swelife
Swelife – For a competitive life science ecosystem in Sweden
Swelife is a strategic innovation programme, funded by the Swedish Government via the Swedish innovation authority Vinnova, Swedish Energy Agency and Swedish Research Council for Sustainable Development Formas, and by the programme’s partners, and by the programme’s partners. We support collaboration within academia, industry, and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health.
www.swelife.se.
